Please answer each of the following questions and press the Submit button. You can submit your results by using the information provided on the next page.
xxxx	1. FEV1 correlates significantly with asthma care outcomes.  A. True  B. False 2. All of the following have been suggested as markers of airways inflammation in asthma EXCEPT:  A. Exhaled NO  B. Sputum eosinophils  C. Sputum lymphocytes  D. Urine LTE4 3. Distal lung inflammation may result in persistent symptoms despite improvements in FEV1  A. True  B. False 4. CFC propellant based inhaled corticosteroids lead to a higher deposition of corticosteroid in the lungs compared to HFA propellant,  A. True  B. False 5. Which of the following medication(s) combined with inhaled corticosteroids have been shown to help decrease the dosage of inhaled corticosteroid needed to control asthma?  A. Montelukast  B. Cromolyn  C. Salmeterol  D. A and C  E. All of the above 6. High dose inhaled corticosteroids have been associated with which adverse events?  A. Oral thrush  B. Osteoporosis  C. Growth retardation in children  D. A and C  E. All of the above 7. Which of the following best describes the results of the study by Pauwels et al?  A. Addition of formoterol to low and high dose budesonide produced equivalent improvement in FEV sub 1 over a year but the group containing the higher dose of budesonide had 50% fewer severe exacerbations/patient/year.  B. Higher dose budesonide alone was more effective in improving FEV sub 1 than either regimen containing formoterol  C. The combination of low dose budesonide and formoterol was as effective in reducing the frequency of severe exacerbations as the higher dose regimen alone  D. Low dose budesonide alone was as effective as high dose budesonide alone in reducing the nocturnal awakenings from asthma  E. The number of puffs/day of rescue medication was not significantly affected by the addition of formoterol to either low or high dose budesonide 8. When comparing the benefit from adding la long-acting beta agonist (LABA) or a lukotriene modifier (LTM) in patients not controlled on low dose inhaled coticosteroid, which of the following might bias the results in favor of the LABA?  A. Measuring FEV sub 1 2-4 hours after the dose of LABA  B. Selecting patients with FEV < 80% predicted  C. Withdrawing patients whose asthma worsens on LTM  D. Selecting number of severe exacerbations as the primary endpoint  E. Measuring methocholine PC sub 20 hours after the last dose of either LABA or LTM